ONTY Insider Trading Activity and SEC Form 4 Filings
ONTY insider trading summary
No open-market insider purchases or sales of Oncothyreon Inc. (ONTY) have been reported on SEC Form 4 in the past 12 months.
Latest ONTY insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jun 1, 2015 | Diana Hausman | Chief Medical Officer | Buy | $27K (5,747 @ $4.65) |
| Mar 26, 2015 | Daniel K Spiegelman | Director | Buy | $16K (10,000 @ $1.59) |
| Mar 25, 2015 | Daniel K Spiegelman | Director | Buy | $16K (10,000 @ $1.63) |
| Dec 17, 2014 | Biotechnology Value Fund II LP | Insider | Buy | $170K (98,298 @ $1.73) |
| Dec 17, 2014 | Mark N Lampert | 10% Owner | Buy | $170K (98,298 @ $1.73) |
| Dec 17, 2014 | Bvf Partners L P/Il | 10% Owner | Buy | $170K (98,298 @ $1.73) |
| Dec 17, 2014 | Biotechnology Value Fund II LP | Insider | Buy | $96K (55,197 @ $1.73) |
| Dec 17, 2014 | Bvf Partners L P/Il | 10% Owner | Buy | $96K (55,197 @ $1.73) |
| Dec 17, 2014 | Biotechnology Value Fund L P | Insider | Buy | $170K (98,298 @ $1.73) |
| Dec 17, 2014 | Mark N Lampert | 10% Owner | Buy | $96K (55,197 @ $1.73) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.